AcuCort AB
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACUC.ST research report →
Companywww.acucort.com
AcuCort AB (publ) develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions. It offers Zeqmelit, a medicine used for the treatment of severe and acute allergic reactions, croup in children, and chemotherapy-induced nausea and vomiting, as well as for the treatment of COVID-19 patients who need supplemental oxygen treatment. AcuCort AB (publ) was incorporated in 2006 and is based in Lund, Sweden.
- CEO
- Jonas Jonmark
- IPO
- 2017
- Employees
- 4
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $163.64M
- P/E
- -6.00
- P/S
- 241.00
- P/B
- 2.79
- EV/EBITDA
- -6.99
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 863.33%
- Op Margin
- -3940.80%
- Net Margin
- -3902.65%
- ROE
- -40.59%
- ROIC
- -47.02%
Growth & Income
- Revenue
- $687.00K · 1.78%
- Net Income
- $-26,190,000 · -50.53%
- EPS
- $-0.22 · -83.33%
- Op Income
- $-26,493,000
- FCF YoY
- 100.00%
Performance & Tape
- 52W High
- $0.95
- 52W Low
- $0.50
- 50D MA
- $0.68
- 200D MA
- $0.65
- Beta
- 1.38
- Avg Volume
- 676.09K
Get TickerSpark's AI analysis on ACUC.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ACUC.ST Coverage
We haven't published any research on ACUC.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ACUC.ST Report →